Richter, Antonia http://orcid.org/0000-0003-0210-6987
Knorr, Karina
Schlapschy, Martin
Robu, Stephanie
Morath, Volker http://orcid.org/0000-0001-7636-0537
Mendler, Claudia
Yen, Hsi-Yu http://orcid.org/0000-0003-2644-2782
Steiger, Katja http://orcid.org/0000-0002-7269-5433
Kiechle, Marion
Weber, Wolfgang
Skerra, Arne http://orcid.org/0000-0002-5717-498X
Schwaiger, Markus
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (SFB824)
Article History
Received: 26 July 2019
Revised: 13 March 2020
Accepted: 23 March 2020
First Online: 20 April 2020
Compliance with Ethical Standards
:
: Martin Schlapschy and Arne Skerra are cofounders and shareholders of XL-protein GmbH, Germany. Wolfgang Weber is on advisory boards and receives compensation from Bayer, Blue Earth Diagnostics, Endocyte, and Pentixapharm and has received research support from BMS, Imaginab, Ipsen, and Piramal. Antonia Richter, Karina Knorr, Stephanie Robu, Volker Morath, Claudia Mendler, His-Yu Yen, Katja Steiger, Marion Kiechle, and Markus Schwaiger, declare that they have no conflict of interest. This work was partly funded by the Deutsche Forschungsgemeinschaft, Germany, in frame of the Collaborative Research Center 824.
: In vivo imaging was offered to support individual therapy planning based on a clinical indication in compliance with the updated Declaration of Helsinki, § 37 “Unproven Interventions in Clinical Practice”, The German Medicinal Products Act (Arzneimittelgesetz) AMG §13 2b, and in accordance with the responsible regulatory authority (General Administration of Upper Bavaria, Germany).
: Informed consent regarding the experimental nature of <sup>89</sup>Zr∙Df-HER2-Fab-PAS<sub>200</sub> as an individual treatment concept was obtained from the patient.